title: Plasma glucose-lowering action of allantoin is induced by activation of imidazoline I-2 receptors in streptozotocin-induced diabetic rats.
abstract: Allantoin, an active principle of yam, is documented to lower plasma glucose in diabetic rats. However, action mechanisms of allantoin remain obscure. It has been indicated that metformin shows ability to activate imidazoline I-2 receptors (I-2R) to lower blood sugar. Allantoin has also a chemical structure similar to metformin; both belong to guanidinium derivative. Thus, it is of special interest to know the effect of allantoin on I-2R. In the present study, the marked plasma glucose-lowering action of allantoin in streptozotocin-induced type-1 like diabetic rats was blocked by specific I-2R antagonist, BU224, in a dose-dependent manner. Also, the increase of β-endorphin release by allantoin was blocked by BU224 in the same manner. Otherwise, amiloride at the dose sufficient to block I-2AR abolished the allantoin-induced β-endorphin release and inhibited the blood glucose-lowering action of allantoin markedly but not completely. The direct effect of allantoin on glucose uptake in isolated skeletal muscle was also blocked by BU224. Also, the phosphorylation of AMPK in isolated skeletal muscle was raised by allantoin in a concentration-dependent manner. More-over, insulin sensitivity in diabetic rats was markedly increased by allantoin and this action was also blocked by BU224. These results suggest that allantoin has an ability to activate imidazoline I-2R while I-2AR is linked to the increase of β-endorphin release and I-2BR is related to other actions including the influence in skeletal muscle for lowering of blood glucose in type-1 like diabetic rats. Thus, allantoin can be developed to treat diabetic disorders in the future.
authors.affiliation: Department of Neurology, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan.
authors.forename: K-C
authors.initials: KC
authors.lastname: Lin
authors.forename: L-R
authors.initials: LR
authors.lastname: Yeh
authors.forename: L-J
authors.initials: LJ
authors.lastname: Chen
authors.forename: Y-J
authors.initials: YJ
authors.lastname: Wen
authors.forename: K-C
authors.initials: KC
authors.lastname: Cheng
authors.forename: J-T
authors.initials: JT
authors.lastname: Cheng
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000481:Allantoin / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects*; D003921:Diabetes Mellitus, Experimental / Q000097:blood* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D007093:Imidazoles / Q000494:pharmacology; D054755:Imidazoline Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007328:Insulin / Q000494:pharmacology; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000201:enzymology; D010766:Phosphorylation / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D034421:Sus scrofa; D001615:beta-Endorphin / Q000378:metabolism
chemical_list: C105826:BU 224; D001786:Blood Glucose; D007093:Imidazoles; D054755:Imidazoline Receptors; D007328:Insulin; C487767:imidazoline receptor 2; D000481:Allantoin; D001615:beta-Endorphin; D055372:AMP-Activated Protein Kinases